Are we over-treating with checkpoint inhibitors?

British Journal of Cancer, Published online: 17 September 2019; doi:10.1038/s41416-019-0570-yAnti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using evidence from melanoma research, both published and in process.
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research